| 4.97 -0.43 (-7.96%) | 04-18 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 11.8  |
1-year : | 15.65 |
| Resists | First : | 10.1 |
Second : | 13.39 |
| Pivot price | 8.84 |
|||
| Supports | First : | 4.77 |
Second : | 3.97 |
| MAs | MA(5) : | 6.26 |
MA(20) : | 9.4 |
| MA(100) : | 13.12 |
MA(250) : | 21.41 |
|
| MACD | MACD : | -1.8 |
Signal : | -1.3 |
| %K %D | K(14,3) : | 1.8  |
D(3) : | 4.1 |
| RSI | RSI(14): 19.5 |
|||
| 52-week | High : | 42.59 | Low : | 4.77 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ AGEN ] has closed above bottom band by 3.4%. Bollinger Bands are 88.3% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 2 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 6.18 - 6.24 | 6.24 - 6.28 |
| Low: | 4.67 - 4.74 | 4.74 - 4.77 |
| Close: | 4.9 - 5 | 5 - 5.06 |
Agenus Inc., a clinical-stage immuno-oncology company, discovers and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies. It develops vaccine programs comprising Prophage vaccine candidate; and QS-21 Stimulon adjuvant, a saponin-based vaccine adjuvant. The company also develops Balstilimab, an anti-PD-1 antagonist that has completed Phase II clinical trial to treat second line cervical cancer; AGEN1181, an anti-CTLA-4 monospecific antibody that is in Phase 1/2 clinical trial; AGEN2373, an anti-CD137 monospecific antibody that is in Phase 1 clinical trial; AGEN1423, a tumor microenvironment conditioning anti-CD73/TGFß TRAP bi-functional antibody that has completed Phase 1 clinical trial; AGEN1777, an anti-TIGIT bispecific antibodies; and AGEN1327, a human monoclonal antibody. In addition, the company develops INCAGN1876, an anti-GITR monospecific antibody; INCAGN1949, an anti-OX40 monospecific antibody; INCAGN2390, an anti-TIM-3 monospecific antibody; INCAGN2385, an anti-LAG-3 monospecific antibody; MK-4830, a monospecific antibody targeting ILT4; AGENT 797, an iNKT cells that is in Phase 1 clinical trial for solid tumors, multiple myeloma, and viral ARDS, as well as in clinical stage to treat hematological malignancies and multiple myeloma/B cells; and AGEN1884, a first-generation anti-CTLA-4 monospecific antibody. Agenus Inc. operates under ASV, Agenus, AutoSynVax, EVAMPLIX, MiNK, PSV, PhosPhoSynVax, Prophage, Retrocyte Display, and Stimulon trademarks. It has collaborations with Incyte Corporation, Merck Sharpe & Dohme, Recepta Biopharma SA, and Gilead Sciences, Inc. The company was formerly known as Antigenics Inc. and changed its name to Agenus Inc. in January 2011. Agenus Inc. was founded in 1994 and is headquartered in Lexington, Massachusetts.
Wed, 17 Apr 2024
Has Agenus (AGEN) Outpaced Other Medical Stocks This Year? - Yahoo Lifestyle UK
Fri, 05 Apr 2024
Agenus Announces Reverse Stock Split of Common Stock - Business Wire
Fri, 29 Mar 2024
Benign Growth For Agenus Inc. (NASDAQ:AGEN) Underpins Stock's 25% Plummet - Simply Wall St
Sun, 17 Mar 2024
US$5.50: That's What Analysts Think Agenus Inc. (NASDAQ:AGEN) Is Worth After Its Latest Results - Yahoo Finance
Fri, 15 Mar 2024
Agenus Inc.'s Future at Risk: Concerns Over Financial Health and Operational Viability - TipRanks.com - TipRanks
Thu, 14 Mar 2024
Agenus Inc. (AGEN) Q4 2023 Earnings Call Transcript - Seeking Alpha
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 21 (M) |
| Shares Float | 18 (M) |
| Held by Insiders | 1.2 (%) |
| Held by Institutions | 59 (%) |
| Shares Short | 2,390 (K) |
| Shares Short P.Month | 2,260 (K) |
| EPS | -13.81 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | -8.14 |
| Profit Margin | -157.3 % |
| Operating Margin | -5.2 % |
| Return on Assets (ttm) | -27.6 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | 195.1 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 7.46 |
| EBITDA (p.s.) | -7 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -224 (M) |
| Levered Free Cash Flow | -87 (M) |
| PE Ratio | -0.37 |
| PEG Ratio | 0 |
| Price to Book value | -0.62 |
| Price to Sales | 0.66 |
| Price to Cash Flow | -0.47 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|